Press Releases

Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules

Download PDF

Key Patent Covers Production of Human Proteins Used as Biologics, including EPO, G-CSF, GM-CSF, and IL-2

LOS ANGELES, CA -- (Marketwired) -- 08/09/16 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,410,143 covering the use of electromagnetic stimulation of cells to produce biological molecules. This newly-issued patent covers the production of human biomolecules commonly used as biologics, including EPO, G-CSF, GM-CSF, and IL-2.

The system and process protected by the patent covers the production of therapeutic proteins by stimulating adult stem cells using the Company's proprietary Time-Varying Electromagnetic Field (TVEMF) technology in a proprietary three dimensional bioreactor system. The technology is part of Endonovo's Cytotronics™ platform, which harnesses the bulk electrical properties of tissues and cells, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic properties of cell therapies and to produce human biomolecules.

Biopharmaceuticals, also known as biologics, are pharmaceutical drug products manufactured in, extracted from, or semi-synthesized from biological sources. These drugs differ from traditional chemically synthesized drugs and include vaccines, hormones, blood components, recombinant therapeutic proteins and living cells used in cell therapies. Biologics are commonly used to stimulate the growth of specific blood cell types, such as red and white blood cells, and to mobilize blood stem cells from the bone marrow into the bloodstream allowing for their collection and subsequent transplantation into patients following chemotherapy.

Generating sales of approximately US$6 billion in 2014, and with recent and upcoming patent expirations on a number of biologics by the year 2020, first and next-generation G-CSF products commonly used in the treatment of chemotherapy-induced neutropenia, represent an attractive market for biosimilar and biosuperior proteins, according to Competitor Analysis Series. The market for biosimilar G-CSF is forecasted to grow at a CAGR of 20.2% from 2014 to 2019, reaching a value of $1.1 billion in 2019, according to BCC Research.

Alan Collier, Chief Executive Officer of Endonovo, commented, "The patent issued today represents significant and important protection to our Cytotronics platform allowing us to move forward with the platform's development of while addressing many of the current drawbacks of culturing cells outside of the body to create better cell therapies and biologics."

Mr. Collier went on to say, "Although follow-on biologics represent a lucrative opportunity for some biotechs by potentially costing 20-30 percent less than their brand name counterparts, we are looking at creating next-generation biosuperior proteins that are created using human cells rather than using recombinant-DNA technology in E.coli and yeast systems."

About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive Electroceuticals™. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions, such as acute liver injury and fulminant hepatic failure, using proprietary non-invasive Electroceutical™ devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target inflammation and cell death.

The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.

Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investors: Sign Up for Email Alerts on Endonovo

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108

Source: Endonovo Therapeutics, Inc.